drugset / Trial / NCT01715129
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
Timeline
- Start
- 2013-01
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triptorelin | Other / unclassified | 11.25 mg | Subcutaneous |